Analysis of Self-reported Adverse Reactions to Efavirenz and Drug Interactions in a Population with HIV in Mexico

Overview

Journal Eur J Hosp Pharm

Publisher BMJ Publishing Group

Specialty Pharmacy

Date 2019 Jun 4

PMID 31157050

Citations 2

Authors

Maria Fernanda Martinez-Salazar

Jesus Oaxaca-Navarro

Alfonso Leija-Salas

Sara Garcia-Jimenez

Miguel Angel Sanchez-Aleman

Myrna Deciga-Campos

Affiliations

Soon will be listed here.

Abstract

Objective: To analyse the most frequent self-reported adverse reactions (ARs), the durability and the causes of antiretrovirals (ARVs) regimens change, concomitant treatments and drug interactions related to the use of ARVs in a group of people living with HIV in Cuernavaca, Morelos, Mexico.

Materials And Methods: Cross-sectional study conducted in a clinic specialising in HIV 'CAPASITS-Cuernavaca' in Mexico from February to June 2015. People who wanted to participate were given a questionnaire on demographic characteristics, adherence, concomitant treatments and ARs. To understand the clinical variables, the clinical records were reviewed. Quantitative variables were compared using Student's t-test for normal data and the Mann-Whitney U test for non-normal data. For comparisons between categorical variables, the χ test was used. All tests used a significance level of 0.05.

Results: A total of 96 people participated, and 218 ARs (mean= 2.3±1.9) were found. The most frequently encountered ARs were dizziness (53.1%), insomnia (21.9%) and lucid dreams (17.7%). Twenty-three people (24%) were polymedicated, and 18 potential interactions were detected in 12 people.

Conclusions: The results suggest that a thorough analysis of the possible drug interactions should be performed for polymedicated people on ARV treatment and that a protocol should be designed for the monitoring and management of AR to ensure a good adherence to ARV treatment.

Citing Articles

Assessment of factors associated with potential drug-drug interactions in patients with tuberculosis and HIV/AIDS.

de Resende N, Miranda S, Ceccato M, Moreira Reis A, Haddad J, da Silva D Rev Soc Bras Med Trop. 2021; 54:e01032021.

PMID: 34320130 PMC: 8313099. DOI: 10.1590/0037-8682-0103-2021.

Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice.

Olufunke D, Edidiong A, Oluwatomisin F, Alani A Iran J Basic Med Sci. 2020; 23(11):1462-1470.

PMID: 33235704 PMC: 7671428. DOI: 10.22038/ijbms.2020.47043.10852.

References

Justice A, Chang C, Rabeneck L, Zackin R . Clinical importance of provider-reported HIV symptoms compared with patient-report. Med Care. 2001; 39(4):397-408. DOI: 10.1097/00005650-200104000-00010. View

Ammassari A, Murri R, Pezzotti P, Trotta M, Ravasio L, De Longis P . Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001; 28(5):445-9. DOI: 10.1097/00042560-200112150-00006. View

Ickovics J, Cameron A, Zackin R, Bassett R, Chesney M, Johnson V . Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002; 7(3):185-93. DOI: 10.1177/135965350200700308. View

. [Self-medication in a urban population of Cuernavaca, Morelos]. Salud Publica Mex. 1992; 34(5):554-61. View

de Maat M, de Boer A, Koks C, Mulder J, Meenhorst P, van Gorp E . Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther. 2004; 29(2):121-30. DOI: 10.1111/j.1365-2710.2003.00541.x. View

Haas D, Smeaton L, Shafer R, Robbins G, Morse G, Labbe L . Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005; 192(11):1931-42. DOI: 10.1086/497610. View

Gratacos L, Tuset M, Codina C, Miro J, Mallolas J, Miserachs N . [Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]. Med Clin (Barc). 2006; 126(7):241-5. DOI: 10.1157/13085280. View

Gardner E, Burman W, Maravi M, Davidson A . Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDS. 2006; 20(9):628-36. PMC: 1976283. DOI: 10.1089/apc.2006.20.628. View

Ventura-Cerda J, Minguez-Gallego C, Fernandez-Villalba E, Alos-Alminana M, Andres-Soler J . [Simplified scale for medication adherence related problems in anti-retroviral therapy]. Farm Hosp. 2006; 30(3):171-6. DOI: 10.1016/s1130-6343(06)73968-x. View

10.

de Padua C, Cesar C, Bonolo P, Acurcio F, Guimaraes M . Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil. Braz J Infect Dis. 2007; 11(1):20-6. DOI: 10.1590/s1413-86702007000100007. View

11.

Subbaraman R, Chaguturu S, Mayer K, Flanigan T, Kumarasamy N . Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007; 45(8):1093-101. DOI: 10.1086/521150. View

12.

Lima V, Harrigan R, Bangsberg D, Hogg R, Gross R, Yip B . The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009; 50(5):529-36. PMC: 3606956. DOI: 10.1097/QAI.0b013e31819675e9. View

13.

Jena A, Sachdeva R, Sharma A, Wanchu A . Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic). 2009; 8(5):318-22. DOI: 10.1177/1545109709343967. View

14.

Bucher H, Rickenbach M, Young J, Glass T, Vallet Y, Bernasconi E . Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antivir Ther. 2010; 15(1):31-40. DOI: 10.3851/IMP1475. View

15.

Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H . Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010; 15(3):413-23. DOI: 10.3851/IMP1540. View

16.

Leutscher P, Stecher C, Storgaard M, Larsen C . Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013; 45(8):645-51. DOI: 10.3109/00365548.2013.773067. View

17.

Edelman E, Gordon K, Glover J, McNicholl I, Fiellin D, Justice A . The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013; 30(8):613-28. PMC: 3715685. DOI: 10.1007/s40266-013-0093-9. View

18.

Baeten J, Haberer J, Liu A, Sista N . Preexposure prophylaxis for HIV prevention: where have we been and where are we going?. J Acquir Immune Defic Syndr. 2013; 63 Suppl 2:S122-9. PMC: 3710117. DOI: 10.1097/QAI.0b013e3182986f69. View

19.

Margolis A, Heverling H, Pham P, Stolbach A . A review of the toxicity of HIV medications. J Med Toxicol. 2013; 10(1):26-39. PMC: 3951641. DOI: 10.1007/s13181-013-0325-8. View

20.

De La Torre-Lima J, Aguilar A, Santos J, Jimenez-Onate F, Marcos M, Nunez V . Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infection. HIV Clin Trials. 2014; 15(1):27-35. DOI: 10.1310/hct1501-27. View